TD Cowen analyst Joseph Thome has maintained their bullish stance on QURE stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Thome’s rating is based on several factors that highlight uniQure’s potential despite recent regulatory challenges. The company has shown promising results from its AMT-130 study, particularly in the high-dose group, which demonstrated significant slowing of disease progression. This is supported by positive biomarker evidence, indicating a potential breakthrough in treatment.
Despite the FDA’s unexpected stance on the accelerated approval pathway, uniQure’s management remains confident in the robustness of their data and the potential of AMT-130. They are actively engaging with the FDA to explore viable paths forward, reflecting their commitment to advancing the treatment. The anticipation of further clarity following the receipt of meeting minutes suggests that uniQure is poised to address regulatory concerns effectively, which supports the Buy rating.
In another report released today, Leerink Partners also reiterated a Buy rating on the stock with a $60.00 price target.